AOD-9604 — 5mg | Lipolytic GH Fragment

AOD-9604 is a synthetic modified analog of the C-terminal region of human growth hormone (hGH), consisting of the natural hGH(177-191) sequence with an N-terminal tyrosine substitution. Developed by Metabolic Pharmaceuticals (Australia) and originally investigated through Phase 2 clinical trials for obesity research, AOD-9604 was designed to selectively retain the lipolytic / metabolic activity of full-length growth hormone while eliminating its IGF-1–stimulating and glucose-modifying effects. Unlike intact hGH which activates the GH receptor and downstream IGF-1 axis, AOD-9604 is studied as a “lipolytic-selective” fragment that engages metabolic and adipose tissue pathways without the broader anabolic and insulin-modulating consequences of GH receptor activation. The compound has been investigated in preclinical research for adipocyte biology, fatty acid oxidation, lipolysis pathways, cartilage biology, and metabolic energy expenditure across both cell-culture and rodent obesity research models.

Benefits (Research Focus)

• Lipolytic-selective signaling — studied for adipose tissue research without IGF-1 axis or glucose-modifying activity

• Fatty acid oxidation — investigated for β-oxidation pathway endpoints in adipocyte and metabolic models

• Adipocyte biology — explored for hormone-sensitive lipase (HSL) activation and lipolysis markers

• Cartilage biology research — examined for chondrocyte effects in osteoarthritis and joint research models

• Comparative GH pharmacology — researched for receptor-pathway differentiation versus full-length growth hormone

What Researchers Look At

• Adipocyte receptor interaction and downstream signaling cascade activation

• Hormone-sensitive lipase (HSL) activity and intracellular lipolysis markers

• Comparative pharmacology versus full-length hGH (IGF-1, insulin sensitivity, glucose homeostasis)

• Adipose tissue mass and body composition endpoints in DIO rodent models

• Chondrocyte function and cartilage matrix expression in joint research models

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 5 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: AOD-9604

• Synonyms: AOD9604; Anti-Obesity Drug 9604; HGH Fragment 176-191; Tyr-hGH(177-191)

• Class: Modified hGH C-terminal fragment; lipolytic-selective peptide; 16 amino acids

• Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF)

• Modification: N-terminal tyrosine substitution on native hGH(177-191) sequence; intramolecular disulfide bridge between Cys⁷ and Cys¹⁴

• Formula / M.W.: C₇₈H₁₂₃N₂₃O₂₃S₂, ~1815.06 g/mol

• CAS: 221231-10-3

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• AOD-9604 Batch COA — October 27, 2025

• AOD-9604 VPeptide — April 23, 2026

• AOD-9604 VPeptide — July 14, 2026